In terms of adjuvant therapy, KLT increases cancer cell sensitivity to chemotherapeutics via JAK2/STAT3 and NF-κB pathway modulation, downregulating MDR1, MRP1, and PVT1, while mitigating chemotherapy-related adverse effects. Here, NFKB1 is linked to cancer.